EA202190369A1 - Способ лечения эпилепсии - Google Patents
Способ лечения эпилепсииInfo
- Publication number
- EA202190369A1 EA202190369A1 EA202190369A EA202190369A EA202190369A1 EA 202190369 A1 EA202190369 A1 EA 202190369A1 EA 202190369 A EA202190369 A EA 202190369A EA 202190369 A EA202190369 A EA 202190369A EA 202190369 A1 EA202190369 A1 EA 202190369A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fenfluramine
- epileptic seizure
- racemate
- fact
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 | |
| PCT/US2019/043765 WO2020023923A1 (en) | 2018-07-27 | 2019-07-26 | Method for treating epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190369A1 true EA202190369A1 (ru) | 2021-06-10 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190369A EA202190369A1 (ru) | 2018-07-27 | 2019-07-26 | Способ лечения эпилепсии |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12558326B2 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| MA53488A (fr) * | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| EP3999570A1 (en) * | 2019-07-18 | 2022-05-25 | Basf Se | Allophanate based dispersing agent |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2023034115A1 (en) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| ATE199829T1 (de) * | 1994-06-03 | 2001-04-15 | Thejmde Trust | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3035926T3 (da) * | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| DK3261640T3 (da) * | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| JP2017051788A (ja) | 2016-12-21 | 2017-03-16 | 株式会社三洋物産 | 遊技機 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
- 2019-07-26 US US16/523,568 patent/US12558326B2/en active Active
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021000196A1 (es) | 2021-12-31 |
| CA3106031A1 (en) | 2020-01-30 |
| WO2020023923A1 (en) | 2020-01-30 |
| EP3829558C0 (en) | 2024-07-03 |
| SG11202100682YA (en) | 2021-02-25 |
| MX2021000987A (es) | 2021-06-15 |
| ES2988130T3 (es) | 2024-11-19 |
| IL280128A (en) | 2021-03-01 |
| BR112021001135A2 (pt) | 2021-04-20 |
| KR20210061332A (ko) | 2021-05-27 |
| US12558326B2 (en) | 2026-02-24 |
| CO2021002087A2 (es) | 2021-04-30 |
| US20200030260A1 (en) | 2020-01-30 |
| EP3829558A1 (en) | 2021-06-09 |
| CR20210095A (es) | 2021-06-01 |
| PH12021550176A1 (en) | 2021-10-11 |
| CN112930175A (zh) | 2021-06-08 |
| JP2021530541A (ja) | 2021-11-11 |
| MA53329A (fr) | 2022-03-02 |
| PE20211065A1 (es) | 2021-06-09 |
| EP3829558B1 (en) | 2024-07-03 |
| AU2019310600A1 (en) | 2021-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550176A1 (en) | Method for treating epilepsy | |
| Peterson et al. | Astrocyte glutamate uptake and signaling as novel targets for antiepileptogenic therapy | |
| Duveau et al. | Differential effects of antiepileptic drugs on focal seizures in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy | |
| Lévesque et al. | Paradoxical effects of optogenetic stimulation in mesial temporal lobe epilepsy | |
| PH12022550869A1 (en) | Targeted bifunctional degraders | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| Brandt et al. | Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats | |
| WO2021252538A3 (en) | Advantageous benzofuran compositions for mental disorders or enhancement | |
| Chali et al. | Inhibiting cholesterol degradation induces neuronal sclerosis and epileptic activity in mouse hippocampus | |
| MX2022016061A (es) | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. | |
| BR9602485A (pt) | Método para o tratamento da doença de Parkinson composição farmacêutica primeira composição farmacêutica e método para a obtenção de efeito antiParkinson | |
| SA521430751B1 (ar) | Kcnt1 مثبطات وطرق استخدامها | |
| RU2018115781A (ru) | Условно активные полипептиды | |
| JOP20220061A1 (ar) | علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي | |
| MX2025010483A (es) | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento | |
| Singh et al. | Agmatine for combined treatment of epilepsy, depression and cognitive impairment in chronic epileptic animals | |
| EA201100609A1 (ru) | Способы лечения воспаления | |
| EA202091559A1 (ru) | Способ получения модуляторов соматостатина | |
| MX2022013595A (es) | Metodos de uso de moduladores del canal de calcio tipo t. | |
| Kalita et al. | Phonophobia and brainstem excitability in migraine | |
| Kan et al. | Anticonvulsant effect of dexmedetomidine in a rat model of self-sustaining status epilepticus with prolonged amygdala stimulation | |
| WO2013039956A3 (en) | Compositions and methods for treating mood disorders | |
| WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
| FI3661491T3 (fi) | 3-metyylimetkatinoni käytettäväksi psykoterapeuttisessa interventiossa olevan henkilön hoidossa | |
| EP3943107A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF BRAIN AND NERVOUS SYSTEM DISEASES |